ThuliumV1, PubMed, Curation, bibRecord, 000391

Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers.

Identifieur interne : 000391 ( PubMed/Curation ); précédent : 000390; suivant : 000392

Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers.

Auteurs : Christopher Netsch [Allemagne] ; Thorsten Bach ; Thomas R W. Herrmann ; Andreas J. Gross

Source :

Asian journal of andrology [ 1745-7262 ] ; 2012.

RBID : pubmed:22231295

Descripteurs français

KwdFr :
- Adulte d'âge moyen, Humains, Hyperplasie de la prostate (), Hyperplasie de la prostate (anatomopathologie), Lasers à solide (effets indésirables), Lasers à solide (usage thérapeutique), Mâle, Prostate (), Prostate (anatomopathologie), Qualité de vie, Résultat thérapeutique, Rétention d'urine, Sujet âgé, Sujet âgé de 80 ans ou plus, Taille d'organe, Thulium, Études de suivi, Études prospectives.
MESH :
- anatomopathologie : Hyperplasie de la prostate, Prostate.
- effets indésirables : Lasers à solide.
- usage thérapeutique : Lasers à solide.
- Adulte d'âge moyen, Humains, Hyperplasie de la prostate, Mâle, Prostate, Qualité de vie, Résultat thérapeutique, Rétention d'urine, Sujet âgé, Sujet âgé de 80 ans ou plus, Taille d'organe, Thulium, Études de suivi, Études prospectives.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Follow-Up Studies, Humans, Lasers, Solid-State (adverse effects), Lasers, Solid-State (therapeutic use), Male, Middle Aged, Organ Size, Prospective Studies, Prostate (pathology), Prostate (surgery), Prostatic Hyperplasia (pathology), Prostatic Hyperplasia (surgery), Quality of Life, Thulium, Treatment Outcome, Urinary Retention.
MESH :
- chemical : Thulium.
- adverse effects : Lasers, Solid-State.
- pathology : Prostate, Prostatic Hyperplasia.
- surgery : Prostate, Prostatic Hyperplasia.
- therapeutic use : Lasers, Solid-State.
- Aged, Aged, 80 and over, Follow-Up Studies, Humans, Male, Middle Aged, Organ Size, Prospective Studies, Quality of Life, Treatment Outcome, Urinary Retention.

Abstract

This study compared the efficacy of 70- and 120-w 2-µm thulium:YAG VapoEnucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). A prospective analysis of 84 patients with symptomatic BPO and prostatic enlargement (≥60 ml) who underwent either 70-w (n=44) or 120-w ThuVEP (n=40) non-randomly was carried out. Patient demographics and perioperative and 12-month follow-up data were analysed. The mean prostate volume was 79.90±27.49 ml in patients who had received 70-w ThuVEP, which was less than in those who had received 120-w ThuVEP (88.53±25.10; P=0.033). The mean enucleation (resected weight/laser time, 2.16±1.21 g min(-1) vs. 1.23±0.60 g min(-1); P=0.013), operation efficiency (resected weight/total operation time, 0.76±0.35 g min(-1) vs. 0.42±0.27 g min(-1); P=0.000) and percentage of resected tissue (66.93%±22.79% vs. 45.41%±23.33%; P=0.000) were higher with 120-w treatment compared to 70-w ThuVEP. One patient (1.2% of total patients) (in the 120-w group) required a blood transfusion postoperatively. Sixty-one patients (73%) were available for review at the 12-month follow-up time point. The quality of life (QoL), International Prostate Symptom Score (IPSS), maximum urinary flow rate (Q(max)), postvoiding residual urine (PVR) and prostate volume improved significantly after treatment (P≤0.035) and were not significantly different between those treated with the different devices (70- and 120-w). The median prostate volume reduction was 81.70% and 82.19% with 70- and 120-w ThuVEP, respectively. The incidence of complications was low and did not differ between groups treated with the different devices. Two patients (2.4%) (one per group) had a bladder neck contracture at the follow-up. ThuVEP is a safe and efficacious procedure for the treatment of symptomatic BPO. The incidence of complications was low with both devices. The 120-w thulium:YAG device enhances the effectiveness of ThuVEP with regard to the percentage of resected tissue and the enucleation/operation efficiency.

DOI: 10.1038/aja.2011.167
PubMed: 22231295

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000391

Links to Exploration step

pubmed:22231295

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers.</title>
<author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Asklepios Hospital Barmbek, Hamburg 22291, Germany. c.netsch@asklepios.com</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Urology, Asklepios Hospital Barmbek, Hamburg 22291</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name>
</author>
<author><name sortKey="Herrmann, Thomas R W" sort="Herrmann, Thomas R W" uniqKey="Herrmann T" first="Thomas R W" last="Herrmann">Thomas R W. Herrmann</name>
</author>
<author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J" last="Gross">Andreas J. Gross</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="doi">10.1038/aja.2011.167</idno>
<idno type="RBID">pubmed:22231295</idno>
<idno type="pmid">22231295</idno>
<idno type="wicri:Area/PubMed/Corpus">000391</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000391</idno>
<idno type="wicri:Area/PubMed/Curation">000391</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000391</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers.</title>
<author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Asklepios Hospital Barmbek, Hamburg 22291, Germany. c.netsch@asklepios.com</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Urology, Asklepios Hospital Barmbek, Hamburg 22291</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name>
</author>
<author><name sortKey="Herrmann, Thomas R W" sort="Herrmann, Thomas R W" uniqKey="Herrmann T" first="Thomas R W" last="Herrmann">Thomas R W. Herrmann</name>
</author>
<author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J" last="Gross">Andreas J. Gross</name>
</author>
</analytic>
<series><title level="j">Asian journal of andrology</title>
<idno type="eISSN">1745-7262</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Lasers, Solid-State (adverse effects)</term>
<term>Lasers, Solid-State (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Organ Size</term>
<term>Prospective Studies</term>
<term>Prostate (pathology)</term>
<term>Prostate (surgery)</term>
<term>Prostatic Hyperplasia (pathology)</term>
<term>Prostatic Hyperplasia (surgery)</term>
<term>Quality of Life</term>
<term>Thulium</term>
<term>Treatment Outcome</term>
<term>Urinary Retention</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Humains</term>
<term>Hyperplasie de la prostate ()</term>
<term>Hyperplasie de la prostate (anatomopathologie)</term>
<term>Lasers à solide (effets indésirables)</term>
<term>Lasers à solide (usage thérapeutique)</term>
<term>Mâle</term>
<term>Prostate ()</term>
<term>Prostate (anatomopathologie)</term>
<term>Qualité de vie</term>
<term>Résultat thérapeutique</term>
<term>Rétention d'urine</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Taille d'organe</term>
<term>Thulium</term>
<term>Études de suivi</term>
<term>Études prospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Thulium</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lasers, Solid-State</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Hyperplasie de la prostate</term>
<term>Prostate</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Lasers à solide</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prostate</term>
<term>Prostatic Hyperplasia</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Prostate</term>
<term>Prostatic Hyperplasia</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Lasers, Solid-State</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Lasers à solide</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Organ Size</term>
<term>Prospective Studies</term>
<term>Quality of Life</term>
<term>Treatment Outcome</term>
<term>Urinary Retention</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Humains</term>
<term>Hyperplasie de la prostate</term>
<term>Mâle</term>
<term>Prostate</term>
<term>Qualité de vie</term>
<term>Résultat thérapeutique</term>
<term>Rétention d'urine</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Taille d'organe</term>
<term>Thulium</term>
<term>Études de suivi</term>
<term>Études prospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This study compared the efficacy of 70- and 120-w 2-µm thulium:YAG VapoEnucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). A prospective analysis of 84 patients with symptomatic BPO and prostatic enlargement (≥60 ml) who underwent either 70-w (n=44) or 120-w ThuVEP (n=40) non-randomly was carried out. Patient demographics and perioperative and 12-month follow-up data were analysed. The mean prostate volume was 79.90±27.49 ml in patients who had received 70-w ThuVEP, which was less than in those who had received 120-w ThuVEP (88.53±25.10; P=0.033). The mean enucleation (resected weight/laser time, 2.16±1.21 g min(-1) vs. 1.23±0.60 g min(-1); P=0.013), operation efficiency (resected weight/total operation time, 0.76±0.35 g min(-1) vs. 0.42±0.27 g min(-1); P=0.000) and percentage of resected tissue (66.93%±22.79% vs. 45.41%±23.33%; P=0.000) were higher with 120-w treatment compared to 70-w ThuVEP. One patient (1.2% of total patients) (in the 120-w group) required a blood transfusion postoperatively. Sixty-one patients (73%) were available for review at the 12-month follow-up time point. The quality of life (QoL), International Prostate Symptom Score (IPSS), maximum urinary flow rate (Q(max)), postvoiding residual urine (PVR) and prostate volume improved significantly after treatment (P≤0.035) and were not significantly different between those treated with the different devices (70- and 120-w). The median prostate volume reduction was 81.70% and 82.19% with 70- and 120-w ThuVEP, respectively. The incidence of complications was low and did not differ between groups treated with the different devices. Two patients (2.4%) (one per group) had a bladder neck contracture at the follow-up. ThuVEP is a safe and efficacious procedure for the treatment of symptomatic BPO. The incidence of complications was low with both devices. The 120-w thulium:YAG device enhances the effectiveness of ThuVEP with regard to the percentage of resected tissue and the enucleation/operation efficiency.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22231295</PMID>
<DateCreated><Year>2012</Year>
<Month>03</Month>
<Day>05</Day>
</DateCreated>
<DateCompleted><Year>2012</Year>
<Month>07</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>01</Month>
<Day>28</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-7262</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>14</Volume>
<Issue>2</Issue>
<PubDate><Year>2012</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Asian journal of andrology</Title>
<ISOAbbreviation>Asian J. Androl.</ISOAbbreviation>
</Journal>
<ArticleTitle>Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers.</ArticleTitle>
<Pagination><MedlinePgn>325-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/aja.2011.167</ELocationID>
<Abstract><AbstractText>This study compared the efficacy of 70- and 120-w 2-µm thulium:YAG VapoEnucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). A prospective analysis of 84 patients with symptomatic BPO and prostatic enlargement (≥60 ml) who underwent either 70-w (n=44) or 120-w ThuVEP (n=40) non-randomly was carried out. Patient demographics and perioperative and 12-month follow-up data were analysed. The mean prostate volume was 79.90±27.49 ml in patients who had received 70-w ThuVEP, which was less than in those who had received 120-w ThuVEP (88.53±25.10; P=0.033). The mean enucleation (resected weight/laser time, 2.16±1.21 g min(-1) vs. 1.23±0.60 g min(-1); P=0.013), operation efficiency (resected weight/total operation time, 0.76±0.35 g min(-1) vs. 0.42±0.27 g min(-1); P=0.000) and percentage of resected tissue (66.93%±22.79% vs. 45.41%±23.33%; P=0.000) were higher with 120-w treatment compared to 70-w ThuVEP. One patient (1.2% of total patients) (in the 120-w group) required a blood transfusion postoperatively. Sixty-one patients (73%) were available for review at the 12-month follow-up time point. The quality of life (QoL), International Prostate Symptom Score (IPSS), maximum urinary flow rate (Q(max)), postvoiding residual urine (PVR) and prostate volume improved significantly after treatment (P≤0.035) and were not significantly different between those treated with the different devices (70- and 120-w). The median prostate volume reduction was 81.70% and 82.19% with 70- and 120-w ThuVEP, respectively. The incidence of complications was low and did not differ between groups treated with the different devices. Two patients (2.4%) (one per group) had a bladder neck contracture at the follow-up. ThuVEP is a safe and efficacious procedure for the treatment of symptomatic BPO. The incidence of complications was low with both devices. The 120-w thulium:YAG device enhances the effectiveness of ThuVEP with regard to the percentage of resected tissue and the enucleation/operation efficiency.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Netsch</LastName>
<ForeName>Christopher</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Urology, Asklepios Hospital Barmbek, Hamburg 22291, Germany. c.netsch@asklepios.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bach</LastName>
<ForeName>Thorsten</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Herrmann</LastName>
<ForeName>Thomas R W</ForeName>
<Initials>TR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gross</LastName>
<ForeName>Andreas J</ForeName>
<Initials>AJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2012</Year>
<Month>01</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Asian J Androl</MedlineTA>
<NlmUniqueID>100942132</NlmUniqueID>
<ISSNLinking>1008-682X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>8RKC5ATI4P</RegistryNumber>
<NameOfSubstance UI="D013932">Thulium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Urol. 2004 Sep;172(3):1012-6</RefSource>
<PMID Version="1">15311026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2003 Jul;170(1):149-52</RefSource>
<PMID Version="1">12796668</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Scand J Urol Nephrol. 2004;38(6):472-6</RefSource>
<PMID Version="1">15841780</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2005 Sep;174(3):998-1001; discussion 1001</RefSource>
<PMID Version="1">16094022</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Urology. 2005 Nov;66(5 Suppl):108-13</RefSource>
<PMID Version="1">16194716</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BJU Int. 2006 Jan;97(1):81-4</RefSource>
<PMID Version="1">16336333</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2006 Jan;49(1):87-91</RefSource>
<PMID Version="1">16314033</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2006 Feb;175(2):537-40</RefSource>
<PMID Version="1">16406990</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2006 Sep;50(3):569-73</RefSource>
<PMID Version="1">16704894</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2006 Sep;50(3):563-8</RefSource>
<PMID Version="1">16713070</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2006 Nov;50(5):969-79; discussion 980</RefSource>
<PMID Version="1">16469429</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2007 Apr;177(4):1419-22</RefSource>
<PMID Version="1">17382744</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BJU Int. 2007 Jul;100(1):94-101</RefSource>
<PMID Version="1">17419697</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Urol. 2007 Jun;25(3):263-7</RefSource>
<PMID Version="1">17473926</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Urol. 2007 Jun;25(3):257-62</RefSource>
<PMID Version="1">17530258</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2008 Jan;53(1):160-6</RefSource>
<PMID Version="1">17869409</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BJU Int. 2008 Jan;101(1):131-42</RefSource>
<PMID Version="1">18086107</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2008 Feb;53(2):382-89</RefSource>
<PMID Version="1">17566639</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2008 Apr;53(4):744-9</RefSource>
<PMID Version="1">17475395</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2008 Jul;180(1):246-9</RefSource>
<PMID Version="1">18499179</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Asian J Androl. 2009 May;11(3):277-81</RefSource>
<PMID Version="1">19398957</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Urol. 2009 Aug;27(4):541-5</RefSource>
<PMID Version="1">19184038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>World J Urol. 2010 Feb;28(1):39-43</RefSource>
<PMID Version="1">19669645</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Urology. 2010 Jan;75(1):194-9</RefSource>
<PMID Version="1">19819535</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>BJU Int. 2010 Aug;106(3):368-72</RefSource>
<PMID Version="1">19912204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2010 Sep;58(3):384-97</RefSource>
<PMID Version="1">20825758</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Urology. 1999 Dec;54(6):1012-6</RefSource>
<PMID Version="1">10604700</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Urology. 2002 Oct;60(4):623-7</RefSource>
<PMID Version="1">12385922</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Urol. 2004 Nov;172(5 Pt 1):1926-9</RefSource>
<PMID Version="1">15540757</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D053844">Lasers, Solid-State</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009929">Organ Size</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011467">Prostate</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011470">Prostatic Hyperplasia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D013932">Thulium</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016055">Urinary Retention</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">PMC3735080</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2012</Year>
<Month>1</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>1</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>1</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>7</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pii">aja2011167</ArticleId>
<ArticleId IdType="doi">10.1038/aja.2011.167</ArticleId>
<ArticleId IdType="pubmed">22231295</ArticleId>
<ArticleId IdType="pmc">PMC3735080</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000391 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000391 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Terre
   |area=    ThuliumV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:22231295
   |texte=   Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:22231295" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ThuliumV1

This area was generated with Dilib version V0.6.21.
Data generation: Thu May 12 08:27:09 2016. Site generation: Thu Mar 7 22:33:44 2024

	Serveur d'exploration sur le thulium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le thulium

Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers.

Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki